We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Blue Scientific Background Displaying Antibodies

Episode 2: Detecting and Eliminating Off-Target Binding for Safer Antibody Therapeutics

Webinar  
On-Demand

Want to share this FREE webinar with a colleague?

Fill out the form below, and we shall send your colleague an invitation to the "Episode 2: Detecting and Eliminating Off-Target Binding for Safer Antibody Therapeutics" event.

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Off-target binding remains a major challenge in antibody therapeutic development, contributing to unexpected toxicities and clinical failures. Conventional approaches, such as tissue cross-reactivity studies, can miss problematic interactions, driving the need for more comprehensive strategies to assess specificity and engineer safer molecules.


In this on-demand presentation from Episode 2 of the Therapeutic Antibody Series 2026, explore strategies for detecting and mitigating off-target binding in antibody-based therapeutics. Discover how the Membrane Proteome Array and CDR-Scanning can help uncover unexpected interactions, improve specificity and guide the development of safer, more developable antibody candidates.


Complete the form to access this on-demand presentation and all other episodes in the series.


Key Learning Objectives:

  • Discover how the Membrane Proteome Array identifies off-target interactions across antibodies, bispecifics, ADCs and CAR-T therapies
  • Understand the role of FDA-aligned MPA data in lead selection and IND submissions
  • Learn how CDR-Scanning improves specificity, tunes affinity and enhances developability through parallel antibody engineering
Speaker
A picture of Alexander Hobby, PhD
Alexander Hobby, PhD
Strategic Account Manager
Integral Molecular
Sponsored by

Have a question about our online events and webinars? Get in touch here.
Now Available on Demand!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar

Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter